Cambridge Trust Co. Buys 2,535 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Cambridge Trust Co. boosted its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 179.7% during the second quarter, according to its most recent filing with the SEC. The firm owned 3,946 shares of the company’s stock after buying an additional 2,535 shares during the period. Cambridge Trust Co.’s holdings in Henry Schein were worth $722,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Bluestein R H & Co. raised its stake in shares of Henry Schein by 22.5% in the first quarter. Bluestein R H & Co. now owns 123,224 shares of the company’s stock worth $20,944,000 after buying an additional 22,608 shares in the last quarter. BlackRock Inc. raised its stake in shares of Henry Schein by 2,999.6% in the first quarter. BlackRock Inc. now owns 5,595,279 shares of the company’s stock worth $951,028,000 after buying an additional 5,414,761 shares in the last quarter. Azimuth Capital Management LLC raised its position in shares of Henry Schein by 4.9% in the first quarter. Azimuth Capital Management LLC now owns 36,234 shares of the company’s stock worth $6,159,000 after buying an additional 1,705 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Henry Schein by 0.6% in the first quarter. Dimensional Fund Advisors LP now owns 310,134 shares of the company’s stock worth $52,714,000 after buying an additional 1,831 shares during the period. Finally, Swedbank raised its position in shares of Henry Schein by 1.6% in the first quarter. Swedbank now owns 1,257,291 shares of the company’s stock worth $213,702,000 after buying an additional 19,885 shares during the period. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Shares of Henry Schein, Inc. (HSIC) traded down 0.31% during mid-day trading on Thursday, hitting $169.79. 243,642 shares of the company were exchanged. The company has a market capitalization of $13.42 billion, a P/E ratio of 24.81 and a beta of 1.09. The company has a 50 day moving average of $180.27 and a 200 day moving average of $175.46. Henry Schein, Inc. has a 52 week low of $146.23 and a 52 week high of $186.99. Shares of Henry Schein are scheduled to split on Friday, September 15th. The 2-1 split was announced on Wednesday, August 16th. The newly minted shares will be payable to shareholders after the closing bell on Thursday, September 14th.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, August 8th. The company reported $1.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.73 by $0.02. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The business had revenue of $3.06 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period last year, the company earned $1.64 EPS. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. Equities analysts anticipate that Henry Schein, Inc. will post $7.27 earnings per share for the current year.

A number of equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of Henry Schein from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Northcoast Research raised shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $218.00 target price for the company in a research note on Monday, August 7th. BidaskClub downgraded shares of Henry Schein from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC reaffirmed a “hold” rating and issued a $177.00 price target on shares of Henry Schein in a research note on Friday, July 21st. Finally, Credit Suisse Group reaffirmed a “hold” rating and issued a $160.00 price target on shares of Henry Schein in a research note on Thursday, July 13th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the stock. Henry Schein has a consensus rating of “Hold” and a consensus target price of $185.56.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.